Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that is not squamous type.
- Your tumor has a specific EGFR mutation (like Ex19del, L858R, G719X, S768I, or L861Q).
- Your cancer has grown during or after treatment with osimertinib as your most recent therapy.
- You have had no more than 2 prior EGFR-targeted pills (osimertinib is the only third-generation one allowed).
- You have at least one tumor that can be measured on a scan and has not been previously treated with radiation.
- You are in good general health (able to do daily activities without significant help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study tests a new drug (SYS6010) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than standard treatments and to find a safe dose.
Hear when a new Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.